Drug Type CAR-T |
Synonyms GPC3 orthoCAR-T + orthoIL-2, SYNCAR-002 + STK-009, SYNCAR-002+STK-009 |
Target |
Mechanism GPC3 inhibitors(Glypican-3 inhibitors), IL-2Rβ inhibitors(Interleukin-2 receptor beta chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Synthekine, Inc.Startup |
Active Organization Synthekine, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | US | Synthekine, Inc.Startup | 14 May 2024 |
Lymphoma | Preclinical | US | Synthekine, Inc.Startup | 14 May 2024 |